Piper Sandler Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $690.00

Axon Enterprise (NASDAQ:AXON) had its price target dropped by research analysts at Piper Sandler from $753.00 to $690.00 in a note issued to investors on Wednesday, MarketBeat reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective would indicate a potential upside of 26.47% from the company’s current price.

Several other brokerages have also issued reports on AXON. Royal Bank Of Canada initiated coverage on shares of Axon Enterprise in a research note on Monday, November 17th. They issued an “outperform” rating and a $860.00 price target on the stock. Morgan Stanley reduced their price target on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Barclays decreased their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Finally, UBS Group lowered their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $768.86.

Axon Enterprise Stock Up 23.3%

Shares of NASDAQ:AXON traded up $103.08 during mid-day trading on Wednesday, reaching $545.59. 1,496,956 shares of the stock were exchanged, compared to its average volume of 955,195. The stock’s 50 day simple moving average is $539.81 and its 200-day simple moving average is $628.76. Axon Enterprise has a one year low of $396.41 and a one year high of $885.91. The company has a market cap of $43.05 billion, a P/E ratio of 172.66, a P/E/G ratio of 12.76 and a beta of 1.48. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The business’s revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.08 EPS. As a group, equities research analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $600.00, for a total value of $680,400.00. Following the sale, the chief accounting officer owned 13,740 shares of the company’s stock, valued at approximately $8,244,000. This trade represents a 7.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeri Williams sold 100 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total value of $55,063.00. Following the sale, the director owned 1,316 shares of the company’s stock, valued at approximately $724,629.08. This represents a 7.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 48,040 shares of company stock valued at $27,249,338 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC bought a new position in Axon Enterprise in the 4th quarter valued at approximately $480,000. NewEdge Advisors LLC lifted its holdings in shares of Axon Enterprise by 41.1% during the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares during the period. Empowered Funds LLC grew its stake in shares of Axon Enterprise by 8.4% in the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP increased its holdings in Axon Enterprise by 40.6% in the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC bought a new position in Axon Enterprise during the 2nd quarter worth $284,000. Institutional investors own 79.08% of the company’s stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beats and strong outlook — Axon reported Q4 revenue of about $797M (up ~39% YoY) and non‑GAAP EPS of $2.15, topping Street estimates; management set a 2026 growth outlook and introduced 2028 targets of $6B revenue and improved margins, driving optimism on top‑line momentum. Axon Enterprise beats fourth-quarter profit estimates, shares rise
• Positive Sentiment: AI bookings and product mix — Management cited accelerating AI-driven bookings across its device+software ecosystem, boosting recurring software revenue visibility and investor confidence in higher-margin growth. The maker of Taser stun guns says it’s becoming an AI company as bookings surge
• Positive Sentiment: Federal demand tailwind — Reports point to rising government spending (including DHS/body‑camera initiatives) and increased federal enforcement budgets that benefit Axon’s cameras, TASERs and evidence-management software. Analysts see this as a durable addressable market expansion. Axon shares rise as Taser-maker’s profit gets boost from government spending
• Neutral Sentiment: Analyst reaction — Some brokers reiterated or raised ratings (Needham maintained a Buy with a $600 PT), reflecting improved visibility; market commentary and earnings snapshots are circulating as investors re‑price expectations. Axon: Strong Q4 Momentum and Upgraded Long-Term Outlook Underpin Buy Rating
• Neutral Sentiment: Broader market context — Axon is appearing on “movers” lists as traders position for earnings and macro catalysts (AI names, Nvidia earnings) that can amplify intraday moves but don’t change company fundamentals. These Stocks Are Today’s Movers
• Negative Sentiment: Valuation and execution risk — Despite the beat, AXON still trades at a rich multiple and has faced sharp recent drawdowns amid AI‑related sentiment swings; some commentary warns the stock could fall if execution on aggressive 2028 targets slips. Can Axon Stock Fall To $300?

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.